B+
Bull case
20%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
KMDA
KamadaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.25
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+73.2
Score
AI commentary
The company source and stored earnings transcript confirm a strong Q2 and reaffirmed outlook; an AP/Zacks snapshot also reported revenue and EPS above surveyed expectations. The August 14 anchor price of $7.58 and August 17 finance quote near $7.65 suggest a modestly positive but not decisive post-print reaction. Analyst revisions, options data, short interest and social coverage are unavailable, so this remains a low-coverage monitoring thesis rather than a high-conviction re-rating case.
RankAlpha Sentiment Codex - 2026-08-17
Open post-earnings memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-12eventQ2 earnings beat with FY2026 guidance reaffirmedMedium impact
Q2 revenue reached a record $54.9 million, net income was $9.3 million, and management reaffirmed FY2026 revenue guidance of $200-$205 million and adjusted EBITDA guidance of $50-$53 million. The company cited stronger KEDRAB, VARIZIG, HEPAGAM and operating cash flow. [#IR-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2]
2026-09-17eventCash dividend paymentMedium impact
The company declared a $0.17 per-share dividend payable September 17, 2026, citing record first-half results and liquidity. [#IR-2026-08-17]
2026-10-01eventInitial plasma sales under three-year agreementHigh impact
Kamada expects initial commercial sales under its approximately $50 million plasma supply agreement to begin in Q4 2026, with the contribution included in current guidance. Timing and ramp remain execution-dependent. [#IR-2026-08-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology